Dr Enriqueta Felip, head of the Thoracic Tumours and Head and Neck Cancer Group at VHIO and section head in…
After an initial response to approved tyrosine kinase inhibitors, principally imatinib, most patients with GIST will develop acquired cancer drug…
The multicenter randomized phase III BREAKWATER trial, spearheaded by VHIO, is the first to evaluate the combination of study drugs…
The five-year follow up data from patients in the KEYNOTE-048 trial have been reported, with the participation of Dr. Irene…
Results of long-term survival analysis of the phase III EMPOWER-Cervical 1 multicenter clinical trial show that immune checkpoint inhibitor cemiplimab…
The first pre-specified interim analysis of overall survival data from the phase III IMpower010 trial shows a trend in favor…
Published in the flagship journal of the European Society for Medical Oncology, Annals of Oncology, renowned leaders in the field…
Published in Molecular Cancer Therapeutics*, a journal of the American Association for Cancer Research (AACR), results of a study co-led…
Founded by Cancer Research UK (CRUK) and the National Cancer Institute (NIH-NCI, USA) the Cancer Grand Challenges are internationally funded…
Results of a VHIO co-led retrospective study published in JCO Precision Oncology verify the use of diagnostic archival tissue biopsies…
Many of our Medical Oncologists and Clinical Investigators have just returned from presenting their latest data at the European Society…
Now published in ESMO Perspectives digital magazine, the latest edition of On Target – Colorectal Cancer: guided by the gut?…
